Clinical Trial Update: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating subcutaneously injected epcoritamab plus oral lenalidomide versus intravenous rituximab with gemcitabine and oxaliplatin in adults wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)
• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING